VCFunding Radar
← Back to directory
O

OrbiMed

New York City, NY, United StatesWebsite ↗

OrbiMed is a leading global investment firm dedicated exclusively to the healthcare sector, investing in companies engaged in biopharmaceutical products, medical technologies, medical devices, diagnostics, digital health, and healthcare services. The firm employs a multi-stage, multi-strategy approach, supporting companies from early-stage ventures to large multinational corporations through public equity, private equity, and private credit/royalty investments.

HealthtechPre SeedSeedSeries ASeries BGrowth
Last raised
Aug 2025
10 mo ago
Latest fund size
$1.9B
OrbiMed Royalty and Credit Opportunities Fund V
AUM
$20B
estimated

Funds raised

Capital this firm has raised, newest first

OrbiMed Royalty and Credit Opportunities Fund V
Aug 2025
$1.9B
OrbiMed Private Investments IX
Oct 2023
OrbiMed Asia Partners V
Oct 2023
OrbiMed Royalty & Credit Opportunities IV
Oct 2023
OrbiMed Private Investments VIII
Mar 2021
$1.5B
OrbiMed Asia Partners IV
Mar 2021
$800M
OrbiMed Royalty & Credit Opportunities III
Mar 2021
$1.2B

Recent investments

Companies this firm has funded, newest first

CompanyRoundAmountDateSource
TruNativJun 2026
Congruence Therapeutics$39.5MMar 2026
ThrombolexLeadSeries A$50MMar 2026
QL Biopharma$72.8MMar 2026
Angitia Biopharmaceuticals$130MFeb 2026
MendraSeries A$82MJan 2026
Mirador TherapeuticsSeries B$250MJan 2026
BlossomHill TherapeuticsSeries B$84MDec 2025

Sources

Where this data came from